



THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

April 27, 2021



Daily Change in COVID-19 Cases, US

January 22, 2020 – April 25, 2021

TOTAL Cases Reported Since 1/22/20

31,883,289

NEW Cases Reported to CDC on 4/25/21

34,641

Change in 7-Day Case Average


-20.8%

Current 7-Day Case Average (4/19/21 - 4/25/21)

54,406

Prior 7-Day Case Average (4/12/21 - 4/18/21)

68,711



New Admissions of Patients with Confirmed COVID-19

August 1, 2020 – April 24, 2021

Patients Currently Hospitalized with COVID on 4/24/21

27,672

New Admissions on 4/24/21

3,936

Peak in New Admissions (1/5/21)

17,988

Change in 7-Day Average of New Admissions


-9.1%

Current 7-Day Average of New Admissions (4/18/21 - 4/24/21)

5,107

Prior 7-Day Average of New Admissions (4/11/21 - 4/17/21)

5,621



Daily Change in COVID-19 Deaths, United States

January 22, 2020 – April 25, 2021

TOTAL Deaths Reported Since 1/22/2020

569,272

NEW Deaths Reported to CDC on 4/25/21

294

Change in 7-Day Death Average

-5.6%

Current 7-Day Death Average (4/19/21 - 4/25/21)


661

Prior 7-Day Death Average (4/12/21 - 4/18/21)











700

Forecasted Total Deaths by 5/15/21

579,000 to 596,000



Choosing Safer Activities

		Unvaccinated People	Your Activity	Fully Vaccinated People
		Outdoor		
Safest			Walk, run, or bike outdoors with members of your household	
			Attend a small, outdoor gathering with fully vaccinated family and friends	
			Attend a small, outdoor gathering with fully vaccinated and unvaccinated people	
Less Safe			Dine at an outdoor restaurant with friends from multiple households	
	Least Safe		Attend a crowded, outdoor event, like a live performance, parade, or sports event	

Get a COVID-19 vaccine



Prevention measures not needed



Take prevention measures















Fully vaccinated people: wear a mask

Unvaccinated people: wear a mask, stay 6 feet apart, and wash your hands.

- Safety levels assume the recommended prevention measures are followed, both by the individual and the venue (if applicable).
- CDC cannot provide the specific risk level for every activity in every community. It is important to consider your own personal situation and the risk to you, your family, and your community before venturing out.



Choosing Safer Activities

	Unvaccinated People	Your Activity Indoor	Fully Vaccinated People
Less Safe		Visit a barber or hair salon	
		Go to an uncrowded, indoor shopping center or museum	
		Ride public transport with limited occupancy	
Least Safe		Attend a full-capacity worship service	
		Sing in an indoor chorus	
		Eat at an indoor restaurant or bar	
		Participate in an indoor, high intensity exercise class	

Get a COVID-19 vaccine



Prevention measures not needed



Take prevention measures


Fully vaccinated people: wear a mask

Unvaccinated people: wear a mask, stay 6 feet apart, and wash your hands.

- Safety levels assume the recommended prevention measures are followed, both by the individual and the venue (if applicable).
- CDC cannot provide the specific risk level for every activity in every community. It is important to consider your own personal situation and the risk to you, your family, and your community before venturing out.



Evidence from Clinical Trials, Laboratory Studies and Real-World Experience that COVID-19 Vaccines Can Protect Against SARS-CoV-2 Variants of Interest/Concern



Selected SARS-CoV-2 Variants

B.1.1.7

originally United Kingdom

B.1.429/B.1.427

originally California

B.1.351

originally South Africa

B.1.526

originally New York

P.1

originally Brazil

B.1.617

originally India



Selected SARS-CoV-2 Variants

B.1.1.7

originally United Kingdom

B.1.429/B.1.427

originally California

B.1.351

originally South Africa

B.1.526

originally New York

P.1

originally Brazil


B.1.617

originally India



B.1.1.7 and COVID-19 Vaccines

- Covered well by currently authorized mRNA vaccines and by AstraZeneca, Novavax vaccines
 - clinical trials, laboratory data, real-world data
- Likely covered by J&J vaccine, but more data needed



Selected SARS-CoV-2 Variants

B.1.1.7

originally United Kingdom

B.1.429/B.1.427

originally California

B.1.351

originally South Africa

B.1.526

originally New York

P.1

originally Brazil

B.1.617

originally India



B.1.351 and COVID-19 Vaccines

■ Variable efficacy in clinical trials

Vaccine	Vaccine efficacy	Reference
Johnson & Johnson	64%	Sadoff et al. <i>NEJM</i> , 4/21/2021
Novavax	60% (HIV-seronegative participants)	Shinde et al. <i>medRxiv</i> , 3/3/2021
AstraZeneca	10%	Madhi et al. <i>NEJM</i> , 3/16/2021
Pfizer	100% (n=800) -- 0 cases in vaccine group; 9 cases (6 confirmed as B.1.351) in placebo group	Pfizer and BioNTech press release, 4/1/2021



Selected SARS-CoV-2 Variants

B.1.1.7

originally United Kingdom

B.1.429/B.1.427

originally California

B.1.351

originally South Africa

B.1.526

originally New York

P.1

originally Brazil

B.1.617

originally India



P.1 and COVID-19 Vaccines

- **Variable protection of Coronavac vaccine (Sinopharma) in real-world effectiveness studies**
- **Brazil**
 - 50% effective vs. symptomatic COVID-19 14 days or more after at least one dose in Manaus, where 75% of COVID-19 cases caused by P.1
 - N=2,656 HCW
 - *medRxiv*, 4/7/2021
- **Chile**
 - 67% effective vs. symptomatic COVID-19 14 days or more after 2nd dose in country where P.1 is increasingly prevalent
 - N≥10 million
 - Chilean MOH, 4/16/2021



Selected SARS-CoV-2 Variants

B.1.1.7

originally United Kingdom

B.1.429/B.1.427

originally California

B.1.351

originally South Africa

B.1.526

originally New York

P.1

originally Brazil

B.1.617

originally India



B.1.429/B.1.427 and COVID-19 Vaccines

- Modest loss (2-3x) of neutralizing activity by mRNA vaccine-induced antibodies



Transmission, Infectivity, and Neutralization of a Spike L452R SARS-CoV-2 Variant

X Deng, CH Chiu et al.



The New England Journal of Medicine

Established in 1812 as THE NEW ENGLAND JOURNAL OF MEDICINE AND SURGERY

April 7, 2021

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

X Shen, DC Montefiori et al.



Selected SARS-CoV-2 Variants

B.1.1.7

originally United Kingdom

B.1.351

originally South Africa

P.1

originally Brazil

B.1.429/B.1.427

originally California

B.1.526

originally New York

B.1.617

originally India



B.1.526 and COVID-19 Vaccines

- Modest loss (3-5x) of neutralizing activity by mRNA vaccine-induced antibodies

medRxiv

THE PREPRINT SERVER FOR HEALTH SCIENCES

March 24, 2021

B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies

H Zhao, T Tada et al.

medRxiv

THE PREPRINT SERVER FOR HEALTH SCIENCES

April 22, 2021

Detection and Characterization of the SARS-CoV-2 Lineage B.1.526 in New York

AP West, PJ Bjorkman et al.



Selected SARS-CoV-2 Variants

B.1.1.7

originally United Kingdom

B.1.429/B.1.427

originally California

B.1.351

originally South Africa

B.1.526

originally New York

P.1

originally Brazil

B.1.617

originally India



April 23, 2021



Cold
Spring
Harbor
Laboratory

bioRxiv


THE PREPRINT SERVER FOR BIOLOGY

Neutralization of Variant Under Investigation B.1.617 with Sera of BBV152 Vaccinees

P Yadav, VK Mohan et al.

- Convalescent sera of COVID-19 cases and recipients of BBV152 vaccine (Covaxin, Bharat Biotech) neutralized B.1.617 variant

Neutralizing response of sera from people with Covaxin during phase 2 clinical trials





THE WHITE HOUSE
WASHINGTON

WH.GOV